Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 1, 2025
BioStem to Showcase its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Spring Meeting
GlobeNewswire
·
May 1, 2025
Company to co-exhibit with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three accepted scientific posters will feature BioStem’s advanced allograft portfolio POMPANO BEACH, Fla., May 01, …
Microbix Presenting at the 2025 Bloom Burton Conference
GlobeNewswire
·
May 1, 2025
MISSISSAUGA, Ontario, May 01, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the 2025 Bloom Burton …
Sol-Gel Announces Reverse Share Split
GlobeNewswire
·
May 1, 2025
NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse Split”) of the Company’s issued and outstanding …
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
GlobeNewswire
·
May 1, 2025
Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea’s Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients Event to Replace Atea’s …
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
GlobeNewswire
·
May 1, 2025
― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg …
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
·
May 1, 2025
1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S. Maintaining 2025 Guidance for Galafold, …
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
GlobeNewswire
·
May 1, 2025
LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic …
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 1, 2025
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025 …
Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook
GlobeNewswire
·
May 1, 2025
WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $700.7 million, down 5.0% compared to …
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 1, 2025
4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S …
As Skin Cancer Rates Climb, Canadian Dermatologists Champion Sun Safety Nationwide this May
GlobeNewswire
·
May 1, 2025
OTTAWA, Ontario, May 01, 2025 (GLOBE NEWSWIRE) -- As the warmth of the sun returns and Canadians begin to spend more time outdoors, the Canadian Dermatology Association (CDA) launches its annual Sun Awareness Month campaign. This year’s campaign, through …
Taux de cancer en hausse : les dermatologues tiennent au mois de mai leur campagne nationale sur la prudence au soleil
GlobeNewswire
·
May 1, 2025
OTTAWA, Ontario, 01 mai 2025 (GLOBE NEWSWIRE) -- Alors que la chaleur du soleil nous revient et que les Canadiens commencent à passer plus de temps à l’extérieur, l’Association canadienne de dermatologie (ACD) lance sa campagne annuelle du Mois de la …
Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas
GlobeNewswire
·
May 1, 2025
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation- …
AB Science will publish its 2024 annual financial report on May 9, 2025
GlobeNewswire
·
May 1, 2025
PRESS RELEASE THE COMPANY WILL PUBLISH ITS 2024 ANNUAL FINANCIAL REPORT ON 9 MAY 2025 Paris, May 1st 2025, 10am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, …
AB Science publiera son rapport financier annuel 2024 le vendredi 9 mai 2025
GlobeNewswire
·
May 1, 2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LA PUBLICATION LE 9 MAI 2025 DE SON RAPPORT FINANCIER ANNUEL 2024 Paris, 1er mai 2025, 10h AB Science SA (Euronext - FR0010557264 - AB) annonce aujourd'hui le décalage de la publication de son rapport financier …
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
GlobeNewswire
·
May 1, 2025
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs …
Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs
GlobeNewswire
·
May 1, 2025
Stacey Davis appointed as Chief Business Officer and Chief Financial Officer Clive Wood, Ph.D. joins Enara Board as Non-executive Director Oxford, United Kingdom – May 01, 2025. Enara Bio, a biopharmaceutical company pioneering the development of …
Roquette Completes the Acquisition of IFF Pharma Solutions
GlobeNewswire
·
May 1, 2025
Roquette Completes the Acquisition of IFF Pharma Solutions Lille, May 1, 2025 – Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces the successful completion of its acquisition …
Roquette finalise l’acquisition d’IFF Pharma Solutions
GlobeNewswire
·
May 1, 2025
Roquette finalise l’acquisition d’IFF Pharma Solutions Lille, le 1 mai 2025 – Roquette, un leader mondial des ingrédients d'origine végétale et des excipients pharmaceutiques destinés aux secteurs de la santé et de la nutrition, annonce la finalisation de …
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
GlobeNewswire
·
May 1, 2025
May 1, 2025 Amsterdam, the Netherlands – argenx (Euronext …